Biome Australia Posts Record Half-Year Revenue and Profit as Probiotics Brand Leads Pharmacy Growth

Biome Australia Ltd ( (AU:BIO) ) has shared an announcement.

Biome Australia has reported record results for the first half of fiscal 2026, highlighting strong operational momentum and market traction for its ACTIVATED PROBIOTICS range. The company posted H1 revenue of $12.4 million, including $6.45 million in second-quarter sales, delivered net profit of $1.18 million, and notched eight consecutive quarters of positive EBITDA, underpinned by 40% revenue growth and the launch of a 240-participant human clinical trial for its BMB18 strain in collaboration with La Trobe University.

Management emphasised that all products in the ACTIVATED PROBIOTICS portfolio are growing while preserving margins without discount-heavy promotions, reinforcing the brand’s premium positioning in Australian pharmacy. This combination of accelerating sales, sustained profitability and advancing clinical IP pipeline suggests a strengthening competitive position in the probiotics segment and offers a constructive signal for stakeholders assessing the company’s growth trajectory and innovation strategy.

The most recent analyst rating on (AU:BIO) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.

More about Biome Australia Ltd

Biome Australia is a healthcare company focused on probiotics, with its flagship ACTIVATED PROBIOTICS brand positioned as the fastest-growing probiotic label in Australian pharmacies. The company offers a full product range that is all in growth, maintains full-margin expansion without relying on promotional discounting, and develops proprietary intellectual property supported by clinical research partnerships with institutions such as La Trobe University.

Average Trading Volume: 259,590

Technical Sentiment Signal: Sell

Current Market Cap: A$94.61M

Learn more about BIO stock on TipRanks’ Stock Analysis page.